Clinical trials: Metastases to Brain
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis…
- Trial name
- BLOOM (NCT02228369)
- Testing
- AZD3759, AZD9291
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Breast Cancer
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
This is a multi-institutional, single arm, open label, Phase Ib/II study of abemaciclib in combination with elacestrant in patients with HR+/Her2- breast cancer metastatic to the brain.
- Trial name
- NCT04791384
- Testing
- Abemaciclib, Elacestrant
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Criterium, Inc.
Brain Metastases
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
BT-M01 is a software that has been pre-learned based on a brain metastasis detection model using brain MR images, and clinical decision support system for brain metastasis by automatically analyzing brain MR images by assisting…
- Trial name
- NCT05573815
- Testing
- BT-M01
- Where
- South Korea
- Volunteers
- 558 people
- Sponsor
- Heuron Inc.
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
- Trial name
- NCT03424473
- Testing
- Tucatinib
- Sponsor
- Seagen Inc.
Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor…
- Conditions
- Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM)
- Trial name
- NCT07751744
- Testing
- JBI-778
- Volunteers
- 113 people
- Sponsor
- Jubilant Therapeutics Inc.
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases
ANG1005 in Leptomeningeal Disease From Breast Cancer
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated…
- Conditions
- Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
- Trial name
- ANGLeD (NCT03613181)
- Testing
- ANG1005, Physician's Best Choice
- Volunteers
- 150 people
- Sponsor
- Angiochem Inc
Hyperlipidemias, Atherosclerosis
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy.
- Conditions
- Hyperlipidemias, Atherosclerosis, Coronary Heart Disease, Carotid Stenosis
- Trial name
- NCT00536965
- Where
- Austria
- Volunteers
- 951 people
- Sponsor
- AstraZeneca
Stroke
Study to Assess the Safety and Effectiveness of the Penumbra System
This clinical evaluation is a prospective, single-arm, multi-center trial. The purpose of this clinical evaluation is to assess the safety and effectiveness of the Penumbra System in the revascularization of patients presenting…
- Trial name
- NCT00334061
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Penumbra Inc.
Autoimmune Diseases of the Nervous System, Multiple Sclerosis
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
The purpose of this study is to determine whether Tcelna (imilecleucel-T, autologous T-Cell Immunotherapy) is effective in the treatment of secondary progressive multiple sclerosis (SPMS).
- Conditions
- Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression
- Trial name
- Abili-T (NCT01684761)
- Testing
- Tcelna
- Where
- 36 sites in United States, Canada
- Volunteers
- 183 people
- Sponsor
- Opexa Therapeutics, Inc.